Unternehmensübersicht
GeneDx Holdings Corp. operates as a leading genomics enterprise that delivers specialized genetic testing services, primarily focusing on pediatric and rare disease diagnostics through whole exome and genome sequencing technologies. The company functions within the healthcare sector, specifically the diagnostics and research industry, where it leverages data and information services alongside the development of an AI-based platform for next generation sequencing. In terms of scale, the entity maintains a market capitalization of $1.70B and employs a workforce of 1300 individuals to support its extensive operations. The reported annual revenue of $427.54M over the trailing twelve months indicates a substantial operational footprint, positioning the firm as a significant player in the genomic testing landscape despite its current profitability challenges.
Finanzielle Gesundheit
The company generated $427.54M in revenue during the trailing twelve months, yet recorded a net income of -$21,021,000, a disparity that reveals a high cost structure where operating expenses significantly outpace gross earnings. Despite the negative net income, the firm reported an EBITDA of $12.65M, suggesting that while accounting for non-cash items and capital expenditures impacts the bottom line, the core operating cash generation remains positive. The free cash flow stands at $38.06M, which provides the company with essential financial flexibility to fund research and development initiatives or manage capital expenditures without immediate reliance on external financing. Profitability analysis shows a gross margin of 69.7%, indicating efficient cost of goods sold management, contrasted by an operating margin of -10.6% and a profit margin of -4.9%, which highlight substantial overhead costs eroding operational profitability. On the balance sheet, the company holds $171.28M in cash against $113.17M in debt, resulting in a debt-to-equity ratio of 36.72, which characterizes a leveraged capital structure rather than a conservative one. Liquidity is supported by a current ratio of 2.46, demonstrating that the company possesses ample current assets to cover its short-term obligations. Return on equity is -7.6% and return on assets is -1.5%, metrics that collectively indicate that management is currently unable to generate positive returns on the shareholder capital or total asset base deployed in the business.
Bewertungsanalyse
Valuation metrics present a complex picture, with a forward P/E of 28.26 listed while the trailing P/E is N/A due to the reported net losses. The absence of a trailing P/E compared to the existence of a forward P/E implies that the market prices the stock based on anticipated future earnings recovery rather than historical performance. The price-to-book ratio is 5.52, suggesting that the market assigns a significant premium to the company's equity value relative to its net asset book value. Alternative valuation measures include a price-to-sales ratio of 3.98 and an EV/EBITDA of 127.57, which indicate that investors are willing to pay a high multiple for revenue and earnings before interest, taxes, depreciation, and amortization despite current unprofitability. The stock price has fluctuated between a 52-week low of $55.17 and a 52-week high of $170.87, with the current valuation context reflecting high volatility within this wide trading range. The beta of 2.15 indicates that the stock price is expected to be approximately twice as volatile as the broader market, exposing investors to higher systematic risk.
Growth & Income
Revenue growth accelerated to 26.5% year-over-year, signaling strong top-line expansion in the diagnostics market, whereas earnings growth is N/A due to the company's current net loss status. Since the earnings growth metric is unavailable, a direct comparison between earnings and revenue growth rates is not possible, but the revenue trajectory suggests that top-line expansion is currently the primary driver of company activity. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm reinvests all available cash flows and reserves into business operations rather than distributing income to shareholders. This non-dividend profile aligns with the company's stage of development, where capital retention supports its aggressive growth strategy and financial restructuring efforts to achieve profitability.